FDA Questions Efficacy, Safety of Boehringer Female Sex Pill
WASHINGTON - Boehringer Ingelheim GmbH's experimental drug flibanserin, a postsynaptic 5-HT1A agonist and 5-HT2A antagonist, failed to significantly improve a woman's sexual desire in Phase III testing, FDA drug reviewers said.
The studies, however, had demonstrated a statistically significant improvement over placebo in sexually satisfying experiences in women taking the investigational medicine, which has been called "female Viagra."
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter